secwatch / observer
8-K filed July 13, 2023, 7:59 PM ET ticker BCYC CIK 0001761612
other material confidence high sentiment neutral materiality 0.75

Bicycle Therapeutics raises ~$187M net in public offering of 9.4M ADSs at $21.25/sh

BICYCLE THERAPEUTICS PLC

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BICYCLE THERAPEUTICS PLC entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC (Representatives) valued at approximately $187.3 million (effective 2023-07-12).

Action
entry
Agreement
underwriting
Counterparty
Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC (Representatives)
Value
approximately $187.3 million
Effective
2023-07-12
Exact text from the filing
On July 12, 2023, Bicycle Therapeutics plc (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Jefferies LLC and SVB Securities LLC (the “ Representatives ”), as representatives of the several underwriters named therein (collectively, the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 9,411,766 American Depositary Shares (“ ADSs ”), each representing one of the Company’s ordinary shares, nominal value £0.01 per share, and, in lieu of ADSs to investors that so choose, non-voting ordinary shares, nominal value £0.01 per share (“ Non-Voting Ordinary Shares ”), each at a public offering price of $21.25 per share (the “ Offering ”). The net proceeds to the Company from the Offering are expected to be approximately $187.3 million
View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR
accession 0001104659-23-080764
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.